{"id":"nct:NCT07704762","kind":"trial","title":"Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder","authors":["U.S. Army Medical Research and Development Command"],"author_count":1,"year":2026,"published":"2026-07-15","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07704762","source_url":"https://clinicaltrials.gov/study/NCT07704762","archive_url":"https://space-kitty.com/papers/nct:NCT07704762","updated":"2026-07-15","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study is a Phase 2, randomized, double-blind, active-controlled, two-arm, single-site clinical trial designed to evaluate the safety, tolerability, and feasibility of MDMA-Assisted Therapy (MDMA-AT) for Service Members (Active Duty, Guard, or Reserve) diagnosed with moderate-to-severe Post-Traumatic Stress Disorder (PTSD) within a Military Health System (MHS) setting. The trial incorporates Acceptance and Commitment Therapy (ACT) as a core therapeutic modality. Participants will receive MDMA-AT utilizing either full-dose or active-control low-dose MDMA. The trial will also assess a regional referral center model by recruiting participants locally from the National Capital Region and non-locally across the MHS.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["PTSD","Post Traumatic Stress Disorder PTSD","Post Traumatic Stress Disorder"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE2","study_type":"INTERVENTIONAL","enrollment":86,"sponsor":"U.S. Army Medical Research and Development Command","conditions":["PTSD","Post Traumatic Stress Disorder PTSD","Post Traumatic Stress Disorder"],"interventions":["DRUG: TREATMENT ARM: Full dose","DRUG: CONTROL ARM: Active-controlled"],"start_date":"2026-10-01","start_date_type":"ESTIMATED","primary_completion_date":"2028-01-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}